Evaluation of immune checkpoint inhibitor efficacy for solid tumors with <i>CD274</i> (PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwide database

Authors

Hisato Kawakami (ORCID: https://orcid.org/0000-0002-3280-4850)
Yasutaka Chiba (ORCID: https://orcid.org/0000-0002-7261-2351)
Hidetoshi Hayashi (ORCID: https://orcid.org/0000-0001-8787-5587)
Kimio Yonesaka (ORCID: https://orcid.org/0000-0002-0816-5315)
Takayuki Takahama (ORCID: https://orcid.org/0000-0002-0321-6718)
Kazuhiko Nakagawa (ORCID: https://orcid.org/0000-0003-1284-9776)
Tomohiro Nakayama
N. Shiraishi

Institutions

Kindai University Hospital (JP)
Kishiwada City Hospital (JP)
Kindai University (JP)

Publication Details

Journal: Journal for ImmunoTherapy of Cancer
Published: 2024-12-01
DOI: https://doi.org/10.1136/jitc-2024-010130
Citations: 3
Primary Topic: Cancer Immunotherapy and Biomarkers
Type: article
Field-Weighted Citation Impact: 0.85

Funders

Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
AstraZeneca
Eisai
Astellas Pharma
Novartis Pharma
Pfizer Japan
Chugai Pharmaceutical
Eli Lilly Japan
Bayer Yakuhin
Daiichi Sankyo Europe

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Evaluation of immune checkpoint inhibitor efficacy for solid tumors with CD274 (PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwide database

Hisato Kawakami, Yasutaka Chiba, Hidetoshi Hayashi, Kimio Yonesaka et al.

Dec 1, 2024

3 citations

Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and Biomarkers

0.85

article

Evaluation of immune checkpoint inhibitor efficacy for solid tumors with CD274 (PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwide database

Hisato Kawakami, Yasutaka Chiba, Hidetoshi Hayashi, Kimio Yonesaka, Takayuki Takahama, Kazuhiko Nakagawa, Tomohiro Nakayama, N. Shiraishi

December 1, 2024article en

3 citations

Abstract

No abstract available for this paper.

Journal for ImmunoTherapy of CancerVol. 12(12)

Kindai University Hospital (JP), Kishiwada City Hospital (JP), Kindai University (JP)

Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Eisai, Astellas Pharma, Novartis Pharma, Pfizer Japan, Chugai Pharmaceutical, Eli Lilly Japan, Bayer Yakuhin, Daiichi Sankyo Europe

Good health and well-being

Openalex Percentile: Top 21%

Cancer Immunotherapy and Biomarkers

0.85

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Evaluation of immune checkpoint inhibitor efficacy for solid tumors with <i>CD274</i> (PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwide database — Hisato Kawakami, Yasutaka Chiba, et al. · Journal for ImmunoTherapy of Cancer (2024) | TGRS Research Map | TGRS